Chronic Kidney Disease Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Tricida, Otsuka Pharmaceuticals, AstraZeneca

The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.
DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Chronic Kidney Disease Market Report:
• The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2024, Despite facing a setback two years ago when the FDA rejected its initial approval application with a complete response letter, Akebia remained steadfast in its belief in the potential of its oral chronic kidney disease (CKD) anemia medication, Vafseo. The FDA has now granted clearance for Vafseo, specifically for patients suffering from CKD-associated anemia who have been on dialysis for a minimum of three months. This decision has initiated a market competition between Akebia and GSK.
• According to Cheng et al., the global estimated prevalence of Chronic Kidney Disease is 13.4% (11.7-15.1%), and patients with end-stage kidney disease (ESKD) needing renal replacement therapy is estimated between 4.902 and 7.083 million
• According to Center of Disease control and Prevention, Chronic Kidney Disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years (6%)
• Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
• Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
• The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)
• The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

Chronic Kidney Disease Overview
Chronic kidney disease (CKD) is defined by reduced estimated glomerular filtration rate (eGFR

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.